header logo image


Page 536«..1020..535536537538..550560..»

ViaCyte Announces $27 Million Financing to Advance Next Generation Cell Therapies for Diabetes – BioSpace

May 27th, 2020 11:49 am

SAN DIEGO, May 26, 2020 /PRNewswire/ --ViaCyte, Inc., a privately held regenerative medicine company, today announced the close of an approximately $27 million private financing, part of the Series D preferred stock financing entered into in late 2018. Investors included, Bain Capital Life Sciences, TPG Capital, RA Capital Management, Sanderling Ventures, and several individual supporters of the Company. Proceeds from the financing will be used to further advance the Company's multi-product candidate approach to develop medicines that have the potential to transform the way insulin-requiring diabetes is managed, potentially providing a functional cure for patients with type 1 diabetes.

Coinciding with the financing, the Company also appointed Ian F. Smithas Executive Chairperson. Mr. Smith was appointed to the Company's Board of Directors in July 2019 and succeeds Fred Middleton, who remains on the board.

Commenting on the financing, Paul Laikind, Ph.D., Chief Executive Officer and President of ViaCyte, said, "During these difficult times we are grateful for the continued support of our investors as well as our clinical trial participants, whose safety and health remains our focus and commitment. We are steadfast in our mission to deliver potentially life sustaining therapies for patients with insulin-requiring diabetes and to continue the significant progress we have made in the past year. ViaCyte is the first company to demonstrate production of C-peptide, a biomarker for insulin, in patients with type 1 diabetes receiving a stem cell-derived islet replacement. Moving forward, we are optimizing the effectiveness of both PEC-Direct and PEC-Encap, the latter of which incorporates novel device material technology created in collaboration with W.L. Gore & Associates. We are also making important progress on our PEC-QT program with our partner, CRISPR Therapeutics, and are now moving into pre-IND activities. This program is designed to eliminate the need for immuno-suppression and could have a transformative impact on a broader population of insulin-dependent patients."

Dr. Laikind continued, "In conjunction with the closure of the financing, we are also pleased to announce the appointment of Ian F. Smith as our Executive Chairperson, succeeding Fred Middleton. Since joining the board last July, Ian and I have worked closely to accelerate ViaCyte's growth and prepare for the future. We are extremely grateful to Fred for his many years of service as Chairperson of ViaCyte's Board of Directors. Throughout his time leading the Board, Fred provided expert guidance as ViaCyte has consistently broken new ground in the field of regenerative medicine and cell replacement therapies."

Mr. Middleton said, "I am proud to have chaired the Board as ViaCyte developed into a leading company in the regenerative medicine field.I am confident that Ian's unique expertise and executive leadership, specifically with innovative growth-oriented companies, and specifically in corporate strategy and operations, as well as capital markets will help ViaCyte progress its important work and firmly establish itself as a leader in the cell therapy sector."

About ViaCyte's Pipeline

The PEC-Direct product candidate, currently being evaluated in the clinic, delivers ViaCyte's PEC-01 cells (pancreatic islet progenitor cells) in a non-immunoprotective device and is being developed for type 1 diabetes patients who have hypoglycemia unawareness, extreme glycemic lability, and/or recurrent severe hypoglycemic episodes. The PEC-Encap (also known as VC-01) product candidate, also undergoing clinical evaluation, delivers the same pancreatic islet progenitor cells but in an immunoprotective device. PEC-Encap is being developed for all patients with type 1 diabetes. In collaboration with CRISPR Therapeutics, ViaCyte is developing immune-evasive stem cell lines from its proprietary CyT49 cell line. These immune-evasive stem cell lines, which are being used in the PEC-QT program, have the potential to further broaden the availability of cell therapy for all patients with insulin-requiring diabetes, type 1 and type 2. In addition, a pluripotent, immune evasive cell line has the potential to be used to produce any cell in the body, thus enabling many other potential indications.

About ViaCyte

ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte's product candidates are based on directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, which are then implanted in durable and retrievable cell delivery devices. Over a decade ago, ViaCyte scientists were the first to report on the production of pancreatic cells from a stem cell starting point and the first to demonstrate in an animal model of diabetes that, once implanted and matured, these cells secrete insulin and other pancreatic hormones in response to blood glucose levels and can be curative. More recently, ViaCyte demonstrated that when effectively engrafted, PEC-01 cells can mature into glucose-responsive insulin producing cells in patients with type 1 diabetes. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with leading companies including CRISPR Therapeutics and W.L. Gore & Associates. ViaCyte is headquartered in San Diego, California. The Company also has a robust intellectual property portfolio, which includes hundreds of issued patents and pending applications worldwide. ViaCyte is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF. For more information on ViaCyte, please visit http://www.viacyte.comand connect with ViaCyte on Twitter, Facebook, and LinkedIn.

View original content to download multimedia:http://www.prnewswire.com/news-releases/viacyte-announces-27-million-financing-to-advance-next-generation-cell-therapies-for-diabetes-301063742.html

SOURCE ViaCyte, Inc.

See the original post:
ViaCyte Announces $27 Million Financing to Advance Next Generation Cell Therapies for Diabetes - BioSpace

Read More...

Evox Therapeutics Appoints Martin Andrews as Non-Executive Director – P&T Community

May 27th, 2020 11:49 am

OXFORD, England, May 27, 2020 /PRNewswire/ -- Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, is pleased to announce the appointment of Martin Andrews as a Non-Executive Director. Martin is a highly experienced senior pharmaceutical executive with broad R&D, commercial and operational experience, and has deep specialist expertise in rare diseases, gene therapy and vaccines.

Martin is an experienced Non-Executive Director and commercial leader, with a strong track record of strategy development and operational delivery. He has had a long and successful career at GlaxoSmithKline, where he has held many senior positions. Most recently, Martin was Senior Vice President, Rare Diseases. Here, he led the global rare disease business and oversaw the development of a portfolio of ex vivo gene therapies, and the launch of Strimvelis, the world's first life-saving gene therapy for children. Furthermore, under his leadership, GlaxoSmithKline transferred its gene therapy portfolio to Orchard Therapeutics. Prior to that, Martin was Senior Vice President, Global Vaccines Commercial, where he led the development of the growth strategy and transformation of the commercial capability in GlaxoSmithKline's Vaccines division.

Martin has previously held Board positions at Orchard Therapeutics and the Alliance for Regenerative Medicine. He is currently a Non-Executive Director of Freeline Therapeutics, where he brings his commercial expertise to their gene therapy portfolio of drugs.

Dr Antonin de Fougerolles, Chief Executive Officer of Evox, commented:

"We're very pleased to welcome Martin as a Non-Executive Director. With his rare disease drug development experience and strong track-record of commercial success, Martin will be a great asset to the company. His expertise will play an important role in helping guide our business growth."

Commenting on his appointment, Martin Andrews said:

"I'm delighted to be joining the Board of Evox.This is an exciting period for the Company and I believe its technology has the potential to transform how medicines are developed and delivered for patients with conditions that are not possible to treat adequately today, especially those with rare diseases. I am thrilled to be part of the team and look forward to contributing."

About Evox Therapeutics

Evox Therapeutics is a privately held, Oxford-based biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop an entirely new class of therapeutics. Backed by leading life sciences venture capital groups and supported by a comprehensive intellectual property portfolio, Evox's mission is to positively impact human health by creating novel exosome-based therapeutics for the treatment of various severe diseases with limited options for patients and their families. Evox has created substantial proprietary technology to modify exosomes using various molecular engineering, drug loading, and targeting strategies to facilitate targeted drug delivery to organs of interest, including the brain and the central nervous system. Exosome-based drugs have the potential to address some of the limitations of protein, antibody and nucleic acid-based therapies by enabling delivery to cells and tissues that are currently out of reach using other drug delivery technologies, and Evox is leading the development within this emerging therapeutic space.

For further information visit: http://www.evoxtherapeutics.com

View original content:http://www.prnewswire.com/news-releases/evox-therapeutics-appoints-martin-andrews-as-non-executive-director-301065071.html

SOURCE Evox Therapeutics

Read the original post:
Evox Therapeutics Appoints Martin Andrews as Non-Executive Director - P&T Community

Read More...

Global Regenerative Medicine Market Research Report With COVID-19 Update – Cole of Duty

May 27th, 2020 11:49 am

MarketsandResearch.biz has released a new research report titled Global Regenerative Medicine Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2026 to its database which presents an overview of the market on the basis of key parameters such as market size, revenue, sales analysis, and key drivers. The report encompasses all the prime factors, making this report extremely useful to all the entrants and potential investors in the global Regenerative Medicine market. The data simplifies this study using a series of channels, including data ranging from rudimentary data to meticulously drawn estimates. Key drivers, as well as challenges of the market, are discussed in the report. The report provides an in-depth analysis of the market with current and future trends.

The report further talks about the definition, types, applications, and major players of the Regenerative Medicine market in detail. The report offers thorough knowledge about the opportunities in business, market status& forecast, the possibility of generating revenue, regional market by different end-users as well as types and future forecasts of upcoming years. The report looks at market status (2015-2020), competitive scenario, advantages and disadvantages of different products and different market players, industry development trends and insights (2020-2026), and regional dominant participants.

NOTE: Our final report will be revised to address COVID-19 effects on the specific market.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/44907

Below mentioned is the list of few companies engaged in the market: ABS Protection GmbH, Mammut, Clarus Corporation, Backcountry Access, Scott, Ortovox, ARVA, Osprey Packs, The North Face, Dakine, Mystery Ranch, Millet(Calida Group), Motorfist, Deuter,

On the basis of product types of market: Mono Avalanche Airbags, Dual Avalanche Airbags

The study explores the key applications/end-users of the market: Skiing, Climbing, Hiking, Others

Furthermore, the report includes a deep compilation of the respective industry and a detailed overview of its segmentation. The report offers a fundamental outlook of the global Regenerative Medicine markets present status and size in terms of volume and value. The essential data about the vital geographical regions and primitive players has been summarized in the report. The market has been broken down into various segments, regions, end-uses, and players to provide a clear picture of the present market situation. Segmentation of the market highlights the growth prospects and trends impacting these segments.

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/44907/global-regenerative-medicine-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2026

The Geographical Landscape of The Market:

The research offers an analysis of the geographical landscape of the global Regenerative Medicine market, which is divided into regions such as North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa). It includes data about several parameters related to the regional contribution. The study provides information regarding the sales generated through each region and the registered market share. Information related to the growth rate during the forecast period is included in the report. According to the report, the industry is projected to generate significant revenue during the forecast period.

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketsandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketsandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.marketsandresearch.biz

View original post here:
Global Regenerative Medicine Market Research Report With COVID-19 Update - Cole of Duty

Read More...

Regenerative Medicine Market In-deep Analysis And Experts Review Report 2020-2026 – Cole of Duty

May 27th, 2020 11:49 am

Global Regenerative Medicine Market Size, Status And Forecast 2020-2026: It offers detailed research and analysis of key aspects of the global Regenerative Medicine market. This report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Regenerative Medicine market. Market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand. Each trend of the global Regenerative Medicine market is carefully analyzed and researched about by the market analysts.

The global regenerative medicine market size was USD 23,841.5 Million in 2018 and is Projected to Reach USD 151,949.5 Million by 2026

The report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/Regenerative Medicine players in the market. Top Companies in the Global Regenerative Medicine Market: Acelity, DePuy Synthes, Medtronic, Zimmer Biomet, Stryker, MiMedx Group, Organogenesis, UniQure, Cellular Dynamics International, Osiris Therapeutics, Vcanbio, Gamida Cell, Golden Meditech, Cytori Therapeutics, Celgene, Vericel Corporation, Guanhao Biotech, Mesoblast, Stemcell Technologes, Bellicum Pharmaceuticals.and Others.

(Special Offer: Available Flat 30% Discount for a limited time only):

Click Here ToGet Sample Copy of the Report:https://www.marketinsightsreports.com/reports/01311075193/global-regenerative-medicine-market-size-status-and-forecast-2019-2025/inquiry?source=bestresearchreports&Mode=54

This report segments the Global Regenerative Medicine Market on the basis of Types are:

Cell Therapy

Tissue Engineering

Biomaterial

On the basis of Application, the Global Regenerative Medicine Market is segmented into:

DermatologyCardiovascularCNSOrthopedic

Regenerative Medicine Market Outlook:

The oncology segment is likely to augment at the fastest CAGR over 2019-2025 due to the increasing number cancer patients across the globe, and a growing number of clinical trials in oncology indications. Approx. 53% of all current clinical trials are in oncology, such as lymphoma, leukemia, and cancer of breast, colon, brain, pancreas, cervix, bladder, and esophagus, among others.

KEY INDUSTRY DEVELOPMENTS

In 2018, Novartis received EU approval for one-time gene therapy Luxturna, which has been developed to restore vision in people with rare and genetically-associated retinal disease.

In 2018, Novartis received EU approval for its CAR-T cell therapy, Kymriah.

In 2017, Integra LifeSciences launched its product, Integra Dermal Regeneration Template Single Layer Thin for dermal repair defects reconstruction in a one-step procedure.

Browse The Full Report Description and TOC:https://www.marketinsightsreports.com/reports/01311075193/global-regenerative-medicine-market-size-status-and-forecast-2019-2025?source=bestresearchreports&Mode=54

Important Features that are under Offering and Regenerative Medicine Highlights of the Reports:

Detailed overview of Market

This report provides pin-point analysis for changing competitive dynamics.

In-depth market segmentation by Type, Application etc

Historical, current and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape of Regenerative Medicine Market

Strategies of Regenerative Medicine players and product offerings

Potential and niche segments/regions exhibiting promising growth

Finally, Regenerative Medicine Market report is the believable source for gaining the Market research that will exponentially accelerate your business. The report gives the principle locale, economic situations with the item value, benefit, limit, generation, supply, request and Market development rate and figure and so on. This report additionally Present new task SWOT examination, speculation attainability investigation, and venture return investigation.

We also offer customization on reports based on specific client requirement:

Browse More Related Reports;

Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Professional Survey Report 2019

https://www.marketinsightsreports.com/reports/11261589875/global-paroxysmal-nocturnal-hemoglobinuria-treatment-market-professional-survey-report-2019?mode=54

Global Cell Expansion Technologies Market Insights, Forecast To 2025

https://www.marketinsightsreports.com/reports/12261036386/global-cell-expansion-technologies-market-insights-forecast-to-2025?mode=54

Global Stem Cell Assay Market Size, Status And Forecast 2019-2025

https://www.marketinsightsreports.com/reports/06251316704/global-stem-cell-assay-market-size-status-and-forecast-2019-2025?mode=54

How we have factored the effect of Covid-19 in our report:

All the reports that we list have been tracking the impact of COVID-19. Both upstream and downstream of the entire supply chain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

About Us:

MarketInsightsReportsprovides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, Regenerative Medicine trends, and strategic recommendations.

Contact Us:

IrfanTamboli (Head of Sales) Market Insights Reports

Phone: + 1704 266 3234 | +91-750-707-8687

[emailprotected]| [emailprotected]

Read more:
Regenerative Medicine Market In-deep Analysis And Experts Review Report 2020-2026 - Cole of Duty

Read More...

Vegan diet, intense cardio and stem cell therapy How Mike Tyson managed to get ripped at 53 as boxing c – talkSPORT.com

May 27th, 2020 11:49 am

Mike Tyson has attributed his incredible body transformation to stem cell therapy and a rigid vegan diet.

The youngest world heavyweight champion in history ballooned to more than 300lbs in weight at his heaviest almost a decade ago.

However, after drastically changing his diet and implementing revolutionary reparative medication, Iron Mike is looking more streamlined and more devastating than ever.

Tyson is reportedly considering making a return to the squared circle at the age of 53, with an announcement on his opponent expected this week.

Whilst training with UFC legends Vitor Belfort and Henry Cejudo, the former undisputed heavyweight champion displayed a significantly more shredded physique.

Prior to officially announcing his desire to return, Tyson was asked by rapper LL Cool J how he would get fighting fit in just six to eight weeks.

He told Rock the Bells Radio show on SiriusXM: Really I would just change my diet and just do cardio work. Cardio has to start, you have to have your endurance to go and do the process of training.

Mike Tyson

So something to do is get in cardio, I would try and get two hours of cardio a day, make sure you get that stuff in. Youre gonna make sure youre eating the right food.

For me its almost like slave food. Doing what you hate to do but doing it like its nothing. Getting up when you dont want to get up. Thats what it is. Its becoming a slave to life.

People think a slave to life is just enjoying drugs and living your life. Being a slave to life means being the best person you can be, being the best you can possibly be, and when you are at the best you can possibly be is when you no longer exist and nobody talks about you. Thats when youre at your best.

Tyson continued: My mind wouldnt belong to me. My mind would belong to somebody that disliked me enough to break my soul, and I would give them my mind for that period of time.

Six weeks of this and Id be in the best shape Ive ever dreamed of being in. As a matter of fact, Im going through that process right now. And you know what else I did, I did stem-cell research.

Stem-cell research (also known as regenerative medicine) promotes the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives.

It is the latest advancement in organ transplantation and uses cells instead of donor organs, which are limited in supply.

After LL Cool J asked if that meant Tysons white blood cells had been spun and then put back in, Tyson continued: Yes. As they took the blood it was red and when it came back it was almost transfluid [sic], I could almost see through the blood, and then they injected it in me. And Ive been weird ever since, Ive got to get balanced now.

Getty Images - Getty

The necessity to repair the former heavyweight champion was caused by the excessive weight gain following his retirement in 2005 and his hedonistic lifestyle.

Excessive cocaine abuse left the heavyweight in a serious state of bother and led him to adopt a vegan lifestyle.

He told Totally Vegan Buzz: I was so congested from all the drugs and bad cocaine, I could hardly breathe. Tyson also revealed in the interview, I had high blood pressure, was almost dying, and had arthritis.

During aninterviewwith Oprah Winfrey in 2013, Tysoncredits his plant-based diet for saving his life.

Getty Images

He said: Well, my life is different today because I have stability in my life. Im not on drugs.

Im not out on the streets or in clubs and everything in my life that I do now is structured around the development of my life and my family. I lost weight.

I dropped over 100lbs and I just felt like changing my life, doing something different and I became a vegan.

Read this article:
Vegan diet, intense cardio and stem cell therapy How Mike Tyson managed to get ripped at 53 as boxing c - talkSPORT.com

Read More...

Amid COVID 19 Crisis, Joshua Frase Foundation Leads Search Spanning Two Continents to Deliver Ventilator to Ailing Child in Ecuador – PRNewswire

May 27th, 2020 11:49 am

PONTE VEDRA BEACH, Fla., May 26, 2020 /PRNewswire/ --Throughout the pandemic, ventilator support has been in short supply. And for one family in Ecuador, finding a ventilator and getting it flown to the small hospital where their one-year-old son was being treated for a rare neuromuscular disorder seemed an insurmountable task.

But worlds away, two organizations on different continents used their network to not only find one, but get it donated and shipped in the nick of time all through families connected by the same thread -- having children affected by centronuclear and myotubular myopathy disorder.

One-month-old Wilson is now stable and ready to go home in Ecuador thanks the herculean efforts of Florida-based Joshua Frase Foundation and Zusammen Stark! eV (CNM-Together Strong), an association in Germany.

"The families that played a role in giving mechanical breath to this child know all too well the priceless value it holds, especially in that fragile first year with a child diagnosed with a nueromuscular disorder. "Having been through it ourselves, we know that without it, this child would pass," said Alison Rockett Frase, founder of Joshua Frase Foundation.

Wilson, like Alison's late son Joshua for whom the foundation is named, was born with myotubular myopathy, which causes very weak muscles, the patient is unable to eat without a feeding tube and requires a ventilator to breathe.

In Ecuador, the healthcare system cannot provide a portable ventilator for parents to take their child home to live out their life. "That means that his family can either chose to keep him alive and institutionalized or bring him home to perish unless they can find a way to pay for or acquire a home ventilator on their own," explained Frase.

Desperate to bring Wilson home, his family reached out to CNM Together Strong!, the association that helps families with centronuclear myopathies in Germany. They connected with Alison and the Joshua Frase Foundation, known for managing a medical equipment exchange program in the U.S.

"The logistical challenges from one country to the next, from customs and language barriers, to the updating of obsolete equipment were all overcome to save Wilson's life," said Frase. "This story shows that the beauty of humanity knows no boundaries and can span three continents, even when the world has been turned upside down."

For Wilson's parents, the gift was more than just a medical machine. "This was not just a gift of breath, but a gift of life in the truest sense," said Andre Carlozama and Daniel Augalsaca. "The joy and elation of now being able to bring Wilson home is immeasurable."

Both the Joshua Frase Foundation and CNM-Together Strong! in Germany are hoping to help the family with additional medical expenses, including maintenance of the ventilator and for doctor care while he is at home. For donations, please visit http://www.pleasedonate.organd tag "for Willson".

"Although children born with this often-fatal disorder live on borrowed time, it is essential that every family be provided the opportunity to bring their child home to spend quality time outside institutional walls," said Frase. "Every donation will mean so much for this family."

About The Joshua Frase Foundation(JFF) is a 501C3 non-profit organization that was founded in 1996; a year after Paul and Alison's son was born with an ultra rare and fatal neuromuscular disorder. Without hesitation, the foundation began funding cutting-edge research in the area of regenerative medicine, gene therapy and genetics since 1997. JFF's mission is twofold: To find a cure or treatment for centronuclear and myotubular myopathies and to support families whose lives are affected by these disorders. Not only has JFF been able to fund groundbreaking science, pioneering into a curative treatment that has the potential to transform neuromuscular research; it has also built an international community of children and their parents. The foundation's efforts have spearheaded human clinical trials for gene therapy. For more information, please visit http://www.joshuafrase.org.

About ZNM Zusammen Stark! e.V.(CNM Together Strong!) is a self-help association for myotubular myopathy and other centronuclear myopathies (CNM = ZNM). We represent (as of October 2019) 159 individuals from 52 families with a CNM in Germany, the Netherlands and Austria. As a self-help organization our main goal is to connect those affected and their families and to support each other in our daily lives. This is mainly done by our yearly family conference, conference, webinars and our closed Facebook support group. We also actively invest on research to find a treatment for these conditions. For more information please visit https://www.znm-zusammenstark.org/en.

Media Contacts: Alison Rockett Frase, Joshua Frase Foundation904-567-3933 or [emailprotected]Liz Morgan, Liz Morgan PR 904-608-3823 or [emailprotected]

SOURCE Joshua Frase Foundation

http://www.joshuafrase.org

Read the original here:
Amid COVID 19 Crisis, Joshua Frase Foundation Leads Search Spanning Two Continents to Deliver Ventilator to Ailing Child in Ecuador - PRNewswire

Read More...

CRISPR Therapeutics to Participate in Upcoming Investor Conferences – GlobeNewswire

May 27th, 2020 11:49 am

ZUG, Switzerland and CAMBRIDGE, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate virtually in the following investor conferences in June:

Jefferies Global Healthcare ConferenceDate:Tuesday, June 2, 2020Fireside chat: 1:30 p.m. ET

Goldman Sachs 41st Annual Global Healthcare ConferenceDate:Tuesday, June 9, 2020Fireside chat: 9:40 a.m. ET

A live webcast of these events will be available on the "Events & Presentations" page in the Investors section of the Company's website athttps://crisprtx.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.

About CRISPR TherapeuticsCRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit http://www.crisprtx.com.

Investor Contact:Susan Kim+1 617-307-7503susan.kim@crisprtx.com

Media Contact:Rachel EidesWCG on behalf of CRISPR+1 617-337-4167reides@wcgworld.com

The rest is here:
CRISPR Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire

Read More...

First American to Receive Placental Cell Treatment For COVID-19 is an Acclaimed Broadway Scenic Designer – Science Times

May 27th, 2020 11:48 am

Edward Pierce, 49, an acclaimed Broadway set designer for plays like Wicked spent five weeks in a medically induced coma after contracting COVID-19 and was treated at a hospital in Teaneck, New Jersey.

His condition slowly deteriorated due to organ failure, and there seemed to be little hope, so his wife agreed to use an untested method developed by an Israeli biotechnology firm. He made history as the first American to receive placental cells in around 15 parts of his body.

According to the Daily Mail, Pierce was off a ventilator and breathing on his own just within ten days of treatment. The treatment is said to be part of the Food and Drugs Administrations' 'compassionate use.'

Pierce first thought that he had the flu, so doctors only prescribed him medicines and told him to stay home. However, his condition continued to worsen, and then he was admitted to the hospital. Four days later, he was put on a ventilator.

At one point in his stay, doctors had to restart his heart after it stopped when he pulled out his breathing tube. Pierce told The Daily Beast that he felt scared at the time because he does not want to be not in control.

He remembered that doctors asked him to count backwards from 10 and her wife told him that she loves him, and he said it back to her. That was the last thing he remembered before waking up five weeks later.

A lot has happened in those times, including him having kidney failure and needing dialysis. Luckily, he did not have to have that. His wife began thinking of what life would be like if Pierce did not make it. She would receive updates from the hospital, sometimes the news was good, sometimes it was not so good.

According to Pixie, the doctors are running out of options to save her husband. So they ask her to authorize an as-yet-untested treatment that extracts stem cells from human placenta.

Read Also: 115 Healthy Babies have Been Born from Mothers Infected with COVID-19 In India

Pluristem Therapeutics, an Israeli company who pioneered the treatment said that 75% of COVID-19 patients had been taken off the ventilator, according to The Jerusalem Post. The FDA permitted the company to offer the treatment on a case-by-case basis to patients under 'compassionate use.'

Compassionate use is the use of a new unapproved treatment for patients who are seriously ill and has not shown any improvements after every other option has been exhausted.

The proposed treatment includes using cells from the placenta or the intramuscular administration of the company's PLX-PAD, which is used for severe pneumonia caused by COVID-19 and preventing the deterioration of patients towards ARDS and sepsis.

Within ten days, Pierce was taken off a ventilator and started to breathe on his own. Gradually, doctors weaned him off of sedatives, and three days after he woke up, his breathing tubes, feeding tubes, and catheters were all removed.

Finally, on May 1, he was discharged from the hospital after nearly seven weeks of treatment. He was then sent to rehabilitation to rebuild his muscles and regain strength.

Read More: CDC Emphasized COVID-19 Not Easily Spread By Touching Surfaces or Objects

See the original post here:
First American to Receive Placental Cell Treatment For COVID-19 is an Acclaimed Broadway Scenic Designer - Science Times

Read More...

Predicting drug responses using pancreatic cancer organoids and multimodal plate imaging on SelectScience – SelectScience

May 27th, 2020 11:47 am

Pancreatic cancer is a deadly malignancy with few treatment models. Monolayer cell culture has failed to predict patient drug responses in the past. In response to this, a patient-derived organoid (PDO) methodology has been developed that enables the generation of models, from both surgically resected material and biopsies, with a success rate of 75-80%. These cultures enable the molecular dissection of treatment responses and resistance.

Here, Dannielle Engle and Christian Oberdanner will discuss the use of the Tecan SparkCyto to evaluate drug responses in PDO models. In short, PDO models were plated in a 384-well format, allowed to reform, and treated with compounds. The dose-responses of PDO models were compared to several agents using both CellTiter-Glo (Promega) to measure ATP levels, as well as the automated confluence measurement. This methodology provided the same endpoint analyses previously relied upon, plus the dynamic evaluation of changes to cell morphology and confluence. Confluence measurements were found to be comparable to ATP levels. Given the diversity observed amongst pancreatic cancer patients and the PDO models, dynamic measurements provide additional flexibility and information for precision medicine approaches.

Key learning objectives:

Who should attend:

Read the original:
Predicting drug responses using pancreatic cancer organoids and multimodal plate imaging on SelectScience - SelectScience

Read More...

CQuentia joins American Heart Association’s Center for Health Technology & Innovation Innovators’ Network with a focus on Precision Medicine -…

May 27th, 2020 11:47 am

FORT WORTH, Texas, May 27, 2020 /PRNewswire/ --CQuentia joinsthe American Heart Association Center for Health Technology and Innovation (the Center) Innovators' Network, which is focused on building and fostering health technologies and relationships in pursuit of innovative and scalable solutions across the healthcare market.

The Center's Innovators' Network helps its members align and integrate their technology with the Association's science-based health management plans, called CarePlans, to encourage development and adoption of digital healthcare solutions.

CQuentia is a next-generation sequencing FDA CLIA laboratory and data service that brings a comprehensive precision medicine platform to the Association's Innovators' Network. When integrated with the American Heart Association CarePlans, CQuentia combines advanced genomics including pharmacogenomics testing and molecular genetic pathology testing to deliver reliable, accurate and actionable genetic and molecular information in concert with leading science and technology. Providers, hospitals and payers are now actively seeking the means to customize care of their patients based on this type of individualized data.

"What separates CQuentia from other genetic testing laboratories is our platform-agnostic approach to deliver solutions and our ability to create client specific reports and alerts that are personalized to target disease state and comorbidities," said Alan Meeker, CQuentia CEO.

This endeavor aims to couple the knowledge gained from CQuentia's genomic testing to drive better personal adherence and control using the Association's CarePlans and health content.

"It's incredibly encouraging to see CQuentia leveraging best-in-class science from the American Heart Association with the aim of improving health education and health engagement," said Patrick Wayte, senior vice president of the American Heart Association Center for Health Technology and Innovation.

About CQuentia CQuentia is a privately-held molecular testing and laboratory company positioned to provide doctors, governments and employers with rapid, reliable results; enabling them to make informed clinical and population health decisions on how to provide the world with the most appropriate restorative care and infection prevention guidance.

For more information, please visit http://www.cquentia.com/covidtesting

SOURCE CQuentia

http://www.cquentia.com/

Read more:
CQuentia joins American Heart Association's Center for Health Technology & Innovation Innovators' Network with a focus on Precision Medicine -...

Read More...

Biobanks Market – Rising need for replacement organs and the steady advancement in the replacement drive growth of market – BioSpace

May 27th, 2020 11:47 am

Biobanks are essentially repositories for storing biological substances derived from humans, which may include organs, bio-specimens, plasma, saliva, and blood. With a vast rise in the number of organ replacement surgeries globally and significant advancements made in the fields of transfusion and replacement technologies, the role of the biobanks market has become more concrete in the healthcare sector in recent years.

The global biobanks market has witnessed expansion at a significant pace in the recent years owing to the vast rise in prevalence of a number of chronic diseases and the increased demand for personal medicine. The massive rise in incidence rate of conditions such as diabetes, cancer, neurovascular diseases, cardiovascular diseases, and respiratory diseases has compelled government bodies to take stronger actions in terms of investments in biobanks and increasing awareness about them. The global market for biobanks works in coherence with these efforts by adding pace to the process of drug discovery and the treatment of chronic diseases that are caused by activities such as smoking, consumption of alcohol, obesity, and unhealthy lifestyles.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=2321

Heavy investment by a proactive government has boosted the North America biobanks market to the leading position in the global biobanks market, followed closely by Europe. Both regions are home to several bioscience companies and host a large number of drug discovery and research activities. Asia Pacific still remains the region with the most promising growth potential as the region shown high promise owing to an increase in investments from both government and non-government organizations, along with a large and increasingly affluent population base that is gaining awareness about the market.

Global Biobanks Market: Overview

The global biobanks market owes its conception to the rising need for replacement organs and the steady advancement in the replacement and transfusion technologies regarding a number of bodily substances. Though the technology and need to store organs and other bio-entities had been available for a long time, the global biobanks market took on a more important role in the healthcare sector following the increasing research in genomics. In the new millennium, the development of the personalized medicine field has been the vital driver for the global biobanks market. The likely advancement of the latter, thanks to helpful government regulations, is likely to make the crucial difference for the global biobanks market in the near future.

The steady technological advancement in the healthcare sector in the last few decades has now led to a scenario where the full potential of biobanks can be harnessed. As a result, the global biobanks market is projected to exhibit steady growth over the coming years.

Buy this Premium Report @ https://www.tmrresearch.com/checkout?rep_id=2321&ltype=S

Global Biobanks Market: Key Trends

The rising interest in personalized medicine is the prime driver for the global biobanks market. Personalized medicine has only become a viable branch of modern medicine after steady research in genomics and the way various patients react to various medicines. The biobanks market has thus come into the spotlight thanks to their role as a steady supplier of human biomaterials for research as well as direct application. The increasing research in genomics following the findings of the Human Genome Project is thus likely to remain a key driver for the global biobanks market in the coming years.

The utilization of biobanks in stem cell research has been hampered in several regions by ethical concerns regarding the origin of stem cells. Nevertheless, the potential of stem cells in the healthcare sector is immense, and is likely to have a decisive impact on the trajectory of the global biobanks market in the coming years. Many countries have, in recent years, adopted a supportive stance towards stem cell research, aiding the growth of the biobanks market. Continued government support is thus likely to remain vital for the global biobanks market in the coming years.

Global Biobanks Market: Market Potential

The leading role of the U.S. in the global biobanks market is unlikely to change in the coming years. The easy availability of government-supported healthcare infrastructure and the presence of several industry giants in the region has driven the biobanks market in the U.S.

Northwell Health, the largest healthcare provider in New York State, earlier in 2017 initiated a new biobank aimed at creating precision therapies against various types of cancer. Launched in collaboration with Indivumed, the biobank will provide catalogued biomaterials for research into lung, colorectal, breast, and pancreatic cancer. This would enable targeted, gene-specific studies of a variety of cancer samples, leading to a more comprehensive understanding of cancer. Such well-funded collaboration efforts are crucial for the developing biobanks market.

Global Biobanks Market: Geographical Dynamics

Led by the fertile healthcare research scenario in the U.S., North America is likely to retain a dominant share in the global biobanks market in the coming years. Steady support from institutes such as the NIH is likely to be vital for the North America biobanks market.

Check Table of Contents of this Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=2321

Emerging Asia Pacific economies such as India and China could emerge with a significant share in the global biobanks market in the coming years. The healthcare sector in both countries has received steady public or private funding in the last few years. India is also a global leader in medical tourism and is likely to receive an increasing number of patients in the coming years, leading to promising prospects for the global biobanks market in the region.

Global Biobanks Market: Competitive Dynamics

Due to the dynamic nature of the global biobanks market, with advancements in diagnostic fields often determining the direction of the market, the market is heavily fragmented. It is likely to retain a significant degree of fragmentation in the coming years thanks to the diversity in the application segments of the biobanks market. The leading players in the global biobanks market include BioCision, Tecan Group, VWR, Beckman Coulter Inc., and Thermo Fisher Scientific.

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Visit Site: https://www.tmrresearch.com/

Continue reading here:
Biobanks Market - Rising need for replacement organs and the steady advancement in the replacement drive growth of market - BioSpace

Read More...

insideHPC Special Report: HPC and AI for the Era of Genomics – insideHPC

May 27th, 2020 11:47 am

This special report sponsored by Dell Technologies, takes a deep dive into HPC and AI for life sciences in the era of genomics. 2020 will be remembered for the outbreak of the Novel Coronavirus or COVID-19. While infection rates are growing exponentially, the race is on to find a treatment, vaccine, or cure. Governments and private organizations are teaming together to understand the basic biology of the virus, its genetic code, to find what can stop it.

Significant amounts of computing power are aimed at this problem, including using the most powerful high performance computing (HPC) systems in the world today. Finding a cure or eliminating COVID-19 will not only benefit the worldwide population, but will also be the foundation for tackling the next pandemic, which some scientists say will happen in the not too distant future.

This technology guide, insideHPC Special Report: HPC and AI for the Era of Genomics, highlights a lineup of Ready Solutions created by Dell Technologies which are highly optimized and tuned hardware and software stacks for a variety of industries. The Ready Solutions for HPC Life Sciences have been designed to speed time to production, improve performance with purpose-built solutions, and scale easier with modular building blocks for capacity and performance.

Introduction

2020 will be remembered for the outbreak of the Novel Coronavirus or COVID-19. While infection rates are growing exponentially, the race is on to find a treatment, vaccine, or cure. Governments and private organizations are teaming together to understand the basic biology of the virus, its genetic code, to find what can stop it. Significant amounts of computing power are aimed at this problem, including using the most powerful high performance computing (HPC) systems in the world today.[1] Finding a cure or eliminating COVID-19 will not only benefit the worldwide population, but will also be the foundation for tackling the next pandemic, which some scientists say will happen in the not too distant future.[2]

Artificial Intelligence (AI)

Slav Petrovski, Head of Genome Analytics and Informatics at AstraZenecas Centre for Genomics Research (CGR) explains that there is a wide range of uses for AI within this field. He says that the approximately three billion base pairs that make up the human genome can be analyzed through AI to find genetic variations. The next step is to determine the level of confidence to be placed in the differing data to decide if it represents a biological genetic variant.

AI is being combined with traditional HPC simulations to predict more accurate results. Based on previous completed computations, an algorithm is able to determine what the next input or result could be. For example, if protein A shows a possible affinity to kill the Coronavirus, then does protein B (or others) have a better chance or could be more effective?

There are a number AI uses within genomics research that can identify and facilitate drug target interaction. By combining analytical and automated processes with the ongoing study of genomics, a more complete understanding of this field will progress. AI can lead to greater insights into the patterns and anomalies in the data, where humans may not see the correlations at first. By using machine and deep learning techniques, new and more effective medicines can get to patients faster and will be better targeted to fight diseases.

Produvia, a research company, has identified five areas where AI will benefit genomic research moving forward:

Precision Medicine

While AI can benefit genomic research, the end goal is to create treatments that specifically attack the genetic code of the infection or disease, and to create treatments that are tailored to an individuals genetic makeup. To do this requires significant data, computing power, and collaborations that combine expertise from many disciplines.

With a combination of faster and more accurate genomic sequencing with faster computer systems and new algorithms, the movement of discovering what medicine will work best on individual pathogens and patients has moved from research institutions to bedside doctors. Physicians and other healthcare providers now have better, faster and more accurate tools and data to determine optimal treatment plans based on more data. This is especially true for pediatric cancer patients.

Personalized or precision medicine holds the key to innovative approaches to manage diseases on an individual level. Various decisions regarding the management of healthcare to each pathogen and/or individual is customized, based on the knowledge of the genetic or cellular information. Diagnosis of diseases, and the resulting treatments can be tailored for each person. However, a number of challenges exist as this scientific field moves forward, such as regulatory oversight, intellectual property rights and patient privacy.

Worldwide, many countries are dedicating resources and efforts to learn more about genomics and how to apply this knowledge to personalizing medicine. Figure 1 shows the worldwide effort to bring precision medicine to those in need. Figure 2 shows how the cost of decoding a human genome has come down, even faster than Moores Law.

Over the next few weeks we will explore these topics surrounding HPC and AI for life sciences in the era of genomics:

Download the complete insideHPC Special Report: HPC and AI for the Era of Genomics, courtesy of Dell Technologies.

[1] COVID-19 HPC Consortium

[2] Scientists in race to protect humanity from future pandemics

See more here:
insideHPC Special Report: HPC and AI for the Era of Genomics - insideHPC

Read More...

AI & Medicine An Expert in AI-aided Drug Discovery and Medical Applications – Bio-IT World

May 27th, 2020 11:47 am

NEW YORK, NY, UNITED STATES - May 27, 2020 - Recently founded, the New York-based company AI & Medicine is an expert in the field of AI-Powered drug discovery, personalized healthcare and various medical applications. Having launched a unique AI-aided drug discovery platform last month, this company grows quickly with concerted support from many talented researchers and scientists. It offers drug R & D solutions from the perspective of AI for medical institutions and pharmaceutical enterprises worldwide.

AI is transforming the practice of medicine. Owing to its ability to identify meaningful relationships in raw data, AI can be used in multiple medical scenarios. For example, it helps doctors diagnose patients more accurately, make predictions about patients future health, and even recommend better treatments. It is quite fair to say that AI can be applied in nearly every field of medicine.

AI & Medicine can help apply machine learning to solve the following four concrete problems:

Drug Research and Development

Through big data analysis and other technical means, the AI-powered drug discovery platform offered by AI & Medicine can quickly and accurately mine data and select the appropriate lead compounds. Especially in contrast with traditional methods, AI can help save a great deal of time, cost, and energy in a range of steps regarding drug discovery, including drug target discovery, candidate drug discovery, prediction of drug crystal form, ADMET prediction, design and optimization of clinical trials, pharmacovigilance, etc.

Medical Translation

The company's AI technology has accumulated a lot in big data, natural semantic analysis, machine learning and deep neural network. A team of scientist with well-equipped knowledge in medical field is capable of optimizing the medical translation system, offering multilingual translation and at the same time ensure the standard and preciseness of medical translation.

Medical Imaging

AI technology is applied in medical imaging area through imaging analysis and surgical simulation.

Main AI methods include image segmentation, feature extraction, quantitative analysis, comparative analysis, etc. AI is increasingly helping to reveal hidden insights into clinical decision-making, connect patients with resources for self-management, and extract meaning from previously inaccessible, unstructured data assets.

Medical Therapy and Research

The company's Intelligent Inquiry and Guidance platform uses the medical AI engine to accurately identify and match the needs of both doctors and patients. Advanced analytics and machine learning techniques are being used concurrently to help uncover critical insights and best practices from the billions of data elements associated with robotic-assisted surgery. Moreover, AI is also helpful in electronic medical record establishment, literature reading and information extraction.

To learn more information about AI & Medicine's capability in AI-powered drug discovery and medical application, please visit:https://aimed.protheragen.com/solutions.html.

About AI & Medicine

Missioned to helping fulfill the specific drug R&D requirements in the industry, AI & Medicine successfully develops an AI-powered drug discovery platform for medical institutions and pharmaceutical enterprises across the globe, offering a broad and integrated portfolio of medical and scientific solutions in areas like drug R&D, medical translation, medical imaging, medical therapy and research system, and more.

Here is the original post:
AI & Medicine An Expert in AI-aided Drug Discovery and Medical Applications - Bio-IT World

Read More...

Insights on the Worldwide Next-generation Sequencing Industry to 2025 – Featuring Illumina, BGI Group & Perkinelmer Among Others – GlobeNewswire

May 27th, 2020 11:47 am

Dublin, May 27, 2020 (GLOBE NEWSWIRE) -- The "Global Next-generation Sequencing Market By Product (Consumables, Platforms and Services), By Technology (Sequencing by Synthesis, Pyrosequencing, and Other Technologies), By End User, By Application, By Region, Competition, Forecast & Opportunities, 2025" report has been added to ResearchAndMarkets.com's offering.

The Global Next-Generation Sequencing Market is projected to grow at a CAGR of close to 20% to reach USD24 billion during the forecast period.

Enhancing regulatory framework for next-generation sequencing based tests for diagnostics is the key factor for the growth of the Global Next-Generation Sequencing Market during the forecast period. Moreover, advancements in next-generation sequencing coupled with reduction in the price of NGS platforms are some other major factors that are anticipated to bolster the growth of the Global Next-Generation Sequencing Market over the coming years. However, some of the factors that might act as major impediments to the growth of the Global Next-Generation Sequencing Market includes concerns pertaining to the standards of NGS based diagnostics.

The Global Next-Generation Sequencing Market is segmented based on product, technology, end-user, application, region and company. Based on technology, the market can be segmented into sequencing by synthesis, ion semiconductor sequencing, sequencing by ligation, pyrosequencing, single molecule real time sequencing and other technologies. Among them, the sequencing by synthesis (SBS) segment dominated the market until 2019 and is projected to grow with a healthy CAGR over the forecast period due to development of new and advanced NGS platforms along with the rising demand for Illumina's systems as it uses the SBS technology.

Major players operating in the Global Next-Generation Sequencing Market include Illumina, Inc., Thermo Fisher Scientific, Inc, BGI Group, Agilent Technologies, Inc., Qiagen N.V., Hoffmann-La Roche AG, 10x Genomics, Oxford Nanopore Technologies, Takara Bio and others.

Objective of the Study:

The author performed both primary as well as exhaustive secondary research for this study. Initially, researchers sourced a list of service providers across the globe. Subsequently, they conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, researchers could include the service providers which could not be identified due to the limitations of secondary research. The author analyzed new services, distribution channels and presence of all major players across the globe.

The author calculated the market size of the Global Next-Generation Sequencing Market by using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. Researchers sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied.

Key Topics Covered:

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Next-generation Sequencing (NGS) Market Outlook5.1. Market End User & Forecast5.1.1. By Value5.2. Market Share & Forecast5.2.1. By Product (Consumables, Platforms and Services)5.2.1.1. By Consumables (Sample preparation consumables and Other Consumables)5.2.1.2. By Platforms (HiSeq series, MiSeq series, ION Torrent, SOLiD, Pacbio Rs II and Sequel system, Other Sequencing Platforms)5.2.1.3. By Services (Sequencing Services and Data management services)5.2.2. By Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Sequencing by Ligation, Pyrosequencing, Single Molecule Real Time Sequencing and Other Technologies)5.2.3. By End User (Academic & Clinical Research Centers, Pharmaceutical & Biotechnology Companies, Hospitals & Clinics and Others)5.2.4. By Application (Biomarkers & Cancer, Diagnostics, Reproductive Health, Personalized Medicine, Agriculture & Animal Research and Other Applications)5.2.5. By Region5.2.6. By Company (2019)5.2.6.1. By NGS Platform

6. North America Next-generation Sequencing (NGS) Market Outlook6.1. Market End User & Forecast6.2. Market Share & Forecast6.3. North America: Country Analysis

7. Europe Next-generation Sequencing (NGS) Market Outlook7.1. Market End User & Forecast7.2. Market Share & Forecast7.3. Europe: Country Analysis

8. Asia-Pacific Next-generation Sequencing (NGS) Market Outlook8.1. Market End User & Forecast8.2. Market Share & Forecast8.3. Asia-Pacific: Country Analysis

9. Middle East and Africa Next-generation Sequencing (NGS) Market Outlook9.1. Market End User & Forecast9.2. Market Share & Forecast9.3. MEA: Country Analysis

10. South America Next-generation Sequencing (NGS) Market Outlook10.1. Market End User & Forecast10.2. Market Share & Forecast10.3. South America: Country Analysis

11. Market Dynamics11.1. Drivers11.2. Challenges

12. Market Trends & Developments

13. Competitive Landscape (NGS Platform Providers)13.1. Competition Outlook13.2. Company Profiles13.2.1. Illumina, Inc.13.2.2. Thermo Fisher Scientific, Inc13.2.3. BGI Group13.2.4. Perkinelmer13.2.5. Agilent Technologies, Inc.13.2.6. Qiagen N.V.13.2.7. F. Hoffmann-La Roche AG13.2.8. 10x Genomics13.2.9. Oxford Nanopore Technologies13.2.10. Takara Bio

14. Strategic Recommendations

15. About Us & Disclaimer

For more information about this report visit https://www.researchandmarkets.com/r/2rcwyi

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Read the rest here:
Insights on the Worldwide Next-generation Sequencing Industry to 2025 - Featuring Illumina, BGI Group & Perkinelmer Among Others - GlobeNewswire

Read More...

Treating rebound headaches with early preventative meds best choice, study finds – Henry Herald

May 27th, 2020 11:46 am

Your head is pounding yet again. You grab another round of pain meds, only to find they no longer work.

You may be suffering from a MOH -- a medication overuse headache -- brought on when the very medications you relied on for relief suddenly become the enemy.

Some 60 million people around the world suffer from headaches brought on by the overuse of medication. It typically happens to people who suffer from migraines, cluster headaches or tension-type headaches who are using medications that don't work.

When the pain doesn't ease, they take another pill, thus setting the scene for what is often known as a "rebound" headache.

Instead of a headache that might call for pain medications two or three times a week, people with MOH now have a headache nearly every day, typically upon awakening. For many, this is a new level of chronic pain -- and there's no miracle pill to fix it.

Is cold turkey best?

Withdrawal therapy is currently the only treatment for this disorder, sometimes combined with physical or behavioral therapy and preventative medicine treatments, sometimes called "bridge therapies."

Those preventative medicine treatments include anticonvulsants, antidepressants, beta blockers and calcium channel blockers that might help control withdrawal pain without risking medication overuse headaches. At times a patient may be given injections of Botox or antibodies designed to thwart migraines.

But not always. In Denmark, for example, guidelines suggest a complete withdrawal, totally discontinuing any pain medications for two months before other options are provided.

"Withdrawal has been recommended for years in European Guidelines, including the most recent published from May 2020," said Dr. Rigmor Jensen, a professor of headache and neurological pain who directs the Danish Headache Center at the University of Copenhagen, and is lead author on a new study to see if those recommendations were right.

In fact, doctors have long debated whether any preventative treatments were necessary to help patients wean off medications -- believing the vast majority of patients did just as well with a cold-turkey approach.

After all, most withdrawal headaches tend to improve in less than a week, although some patients did need to be hospitalized, especially if they were withdrawing from opioids.

"In placebo-controlled studies for preventive treatment, the effect has been modest," Jensen said. "So, we decided to compare these treatment strategies directly in this study to clarify the question."

Jensen and his coauthors hypothesized that withdrawal alone, or withdrawal with preventatives, would work better in reducing overall headache days per month than a preventative approach.

However, the results of their study, published Tuesday in the journal JAMA Neurology, surprised the authors.

While all three treatments were effective in reducing MOH, the largest reductions in headache and migraine days, days with short-term medication use and days with headache pain intensity were seen in the withdrawal plus preventive medicine group.

In addition, people who withdrew from meds with the help of preventatives had a significantly higher chance of being cured of their medication overuse headaches than patients who used preventatives or withdrawal alone.

"We were surprised of the study results and the excellent adherence to the treatment," Jensen said. "We now recommend withdrawal and early start of preventive treatment."

"Having good medical evidence to support the common practice of both stopping the offending agent or agents, and starting a patient on prevention medication right away, will clear up some of the controversy and confusion," said Dr. Rachel Colman, director of the Low-Pressure Headache Program at the Icahn School of Medicine at Mount Sinai in New York.

Doctors should use this study to "provide patients with guidance, support and hopefully relief from a disabling condition," said Coleman, who was not involved in the study and is a member of the National Headache Foundation Health Care Professionals Leadership Council.

Coleman also pointed out that due to timing of the trial, the study did not include the newest options for prevention, called CGRP monoclonal antibodies, that have become available in the last two years. These are a new class of medication created specifically for migraine headaches.

However, Jensen said that going "cold-turkey" may still have some benefits for patients, especially those with less severe rebound headaches. Prior studies have found that when patients feel their actions exert control over their headaches, it can help them from overusing medications in the future.

"Patients who withdraw completely experience that a headache can disappear by itself, and that experience is important when talking about preventing relapse into a new medication overuse," Jensen said.

What causes a MOH?

Just how much pain medication will cause a rebound headache depends on the medicine.

According to the American Migraine Foundation, over-the-counter pain relievers, such as aspirin, acetaminophen, ibuprofen, naproxen and indomethacin, can cause MOH when used 15 or more days per month.

It will only take about 10 days of use for medications that combine caffeine, aspirin and acetaminophen to contribute to a MOH. Ten days is also the max for tryptamine- and ergotamine-based drugs often prescribed for migraines, as well as any of the opiates: oxycodone, tramadol, butorphanol, morphine, codeine or hydrocodone.

Just 200 milligrams of coffee will also trigger a medication overdose headache. That's just one cup of coffee combined with a coke and a plain chocolate bar.

It's not just pain in the head either. Often MOH can cause memory issues, difficulty concentrating, depression, anxiety, irritability, restlessness and nausea.

Now, more than ever, the world needs trustworthy reportingbut good journalism isnt free.Please support us by subscribing or making a contribution today.

Here is the original post:
Treating rebound headaches with early preventative meds best choice, study finds - Henry Herald

Read More...

Leading Thrombosis Specialists Issue Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients…

May 27th, 2020 11:46 am

CHAPEL HILL, N.C., May 27, 2020 /PRNewswire/ --Leading thrombosis specialists from the International Society on Thrombosis and Haemostasis(ISTH) and World Thrombosis Day(WTD) Steering Committee recommend administering either standard preventative or larger doses of heparin (blood thinning medicine) to combat excessive clotting in all hospitalized COVID-19 patients from the time of hospital admission, unless they have contraindications to those medications.

This proposed "universal" intervention strategy is a change from the current practice of using only preventative levels of such medications after individual venous thromboembolism (VTE) risk assessment of hospitalized patients.

The recommendations are published in a new paper, titled "Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients with COVID-19," published on May 27, 2020 in the Journal of Thrombosis and Haemostasis (JTH). The peer-reviewed paper outlines new practical guidance on the prevention and treatment of VTE in hospitalized patients with COVID-19.

The recommendations were developed by a multidisciplinary panel of thrombosis experts as a response to widespread clinical reports of unusual, difficult-to-control clotting in COVID-19 patients."Early reports suggest COVID-19 is one of the most thrombotic disease states we've ever seen," said lead author Alex Spyropoulos, M.D., member of the WTD Steering Committee. Co-authors include leading scientists from six countries (see below for list).

In issuing new guidance, the authors analyzed reports from colleagues around the world who observed that patients hospitalized with COVID-19 had a high incidence of thrombotic events (blood clots). The authors caution that the data are based on anecdotal reporting rather than rigorous scientific research. Thus, guidance may change as data improves, though the scientists generally agree the recommendations are sufficiently supported to be adopted into practice.

"We consider this a living document," Spyropoulos said. "This is a very fast-moving target. The data are important, but even more important is our need to take care of patients now. We see this correlation with clotting, and we must act."

"In the United Kingdom, we are seeing high rates of blood clots in our patients even as they receive standard doses of blood thinners," said Professor Beverley Hunt, M.D., OBE, WTD Steering Committee Chair. "These patients seem to need larger doses than other sick patients. We need to know the best doses going forward."

Additional research is in development in the UK at this time, via a clinical trial named REMAP-CAP, to capture the response of COVID-19 patients to different dosing levels of blood thinning medications. This will provide more guidance for healthcare professionals globally, Hunt said.

While much remains unknown, the authors have concluded that patients with severe cases of COVID-19 develop VTE at a much higher rate than severely ill patients in general. VTE is a condition in which blood clots form (most often) in the deep veins of the leg (known as deep vein thrombosis or DVT), and can travel in the circulation to lodge in the lungs (known as pulmonary embolism, or PE). The development of this condition in hospitalized COVID-19 patients results in a much higher risk of death, particularly in patients with preexisting cardiovascular disease.

COVID-19 patients in the intensive care unit (ICU) are three to six times more likely to experience DVT than a patient in ICU for some other reason, such as congestive heart failure.

The authors also noted that the clots exhibit particular characteristics. Clots that lead to cardiac events, such as heart attacks and strokes, are typically large. In COVID-19 patients, however, in addition to the usual large clots seen in these patients, smaller clots (microthrombi) are also present in the lungs.

Clinicians have not identified a specific cause of blood clotting in COVID-19 patients, but believe it is due to the extreme immune response to COVID-19 that causes very sticky blood. Early research on COVID-19 found that blood clots are playing a role in a significant percentage of all COVID-19 deaths in the United States. Patients in the United States, however, are not routinely given blood thinners, in contrast to patients in the United Kingdom.

For more information on the paper, "Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients with COVID-19," visit https://onlinelibrary.wiley.com/doi/abs/10.111/jth.14929.

Co-authors include: Jerrold H. Levy (United States), Walter Ageno (Italy), Jean Marie Connors (United States), Beverley J. Hunt (United Kingdom), Toshiaki Iba (Japan), Marcel Levi (United Kingdom), Charles Marc Samama (France), Jecko Thachil (United Kingdom), Dimitrios Giannis (United States), and James D. Douketis (Canada)

SOURCE International Society on Thrombosis and Haemostasis

http://www.isth.org

Read more here:
Leading Thrombosis Specialists Issue Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients...

Read More...

Letter to the editor: Can they hate Trump any more? – TribLIVE

May 27th, 2020 11:46 am

You are solely responsible for your comments and by using TribLive.com you agree to ourTerms of Service.

We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.

While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.

We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers

We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.

We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.

We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.

We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sentvia e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.

Read more here:
Letter to the editor: Can they hate Trump any more? - TribLIVE

Read More...

Drug Touted by Trump as COVID-19 Treatment Tied to Increased Risk of Death: Study – The New York Times

May 27th, 2020 11:46 am

(Reuters) - The anti-malarial drug hydroxychloroquine, which U.S. President Donald Trump says he has been taking and has urged others to use, was tied to an increased risk of death in hospitalized COVID-19 patients, a large study published on Friday showed.

In the study https://www.thelancet.com/lancet/article/s0140673620311806 that looked at more than 96,000 people hospitalized with COVID-19, the respiratory disease caused by the novel coronavirus, those treated with hydroxychloroquine or the related chloroquine had higher risk of death and heart rhythm problems than patients who were not given the medicines.

The study, published in the Lancet medical journal, showed no benefit for coronavirus patients taking the drugs.

Demand for the decades-old hydroxychloroquine has surged as Trump repeatedly promoted its use against the coronavirus, urging people to try it. "What have you got to lose?" he asked.

Trump said this week he has been taking hydroxychloroquine as a preventative medicine despite a lack of scientific evidence.

The Lancet study authors suggested that hydroxychloroquine and chloroquine should not be used to treat COVID-19 outside of clinical trials until studies confirm their safety and efficacy in such patients.

There is a frantic search for drugs to treat COVID-19 at the same time that multiple research teams pursue a safe and effective vaccine to combat a pathogen that has killed more than 335,000 people worldwide and sickened millions more.

The U.S. Food and Drug Administration has allowed healthcare providers to use the drugs for COVID-19 through an emergency-use authorization, but has not approved them to treat it.

Dr. Mandeep Mehra, one of the study's authors, said the research shows that the FDA should withdraw that authorization.

"That will help move this towards more, stronger evidence because it will then force the use of these drugs only in the setting of control trials," Mehra said in an interview. "That would be an extremely wise decision."

The FDA has said that, for safety reasons, hydroxychloroquine should be used only for hospitalized COVID-19 patients or those in clinical trials. The drug has been tied to dangerous heart rhythm problems.

The Lancet study looked at data from 671 hospitals where 14,888 patients were given either hydroxychloroquine or chloroquine, with or without an antibiotic, and 81,144 patients were not given such treatments.

Both drugs have shown evidence of effectiveness against the coronavirus in a laboratory setting, but studies in patients had proven inconclusive. Several small studies in Europe and China spurred interest in using hydroxychloroquine against COVID-19, but were criticized for lacking scientific rigor.

Several more recent studies have not shown the drug to be an effective COVID-19 treatment. Last week, two studies published in the medical journal BMJ showed that patients given hydroxychloroquine did not improve significantly over those who were not.

Hydroxychloroquine is used to treat lupus and rheumatoid arthritis as well as malaria.

Hospitalized patients tend to have a more severe version of COVID-19. Some proponents of the drugs for COVID-19 argue that they may need to be administered at an earlier stage to be effective.

There are ongoing randomized, controlled clinical trials to study the drug's effectiveness in preventing infection by the coronavirus as well as treating mild to moderate COVID-19. Some of those may yield results within weeks.

(Reporting by Ankur Banerjee and Manas Mishra in Bengaluru and Michael Erman in New York; Editing by Saumyadeb Chakrabarty, Bill Berkrot, Jonathan Oatis and Will Dunham)

Original post:
Drug Touted by Trump as COVID-19 Treatment Tied to Increased Risk of Death: Study - The New York Times

Read More...

Drug Touted by Trump as COVID-19 Treatment Tied to Increased Death Risk, Study Finds – Voice of America

May 27th, 2020 11:46 am

WASHINGTON - Malaria drug hydroxychloroquine, which U.S. President Donald Trump says he has been taking, is tied to increased risk of death in COVID-19 patients, according to a study published in medical journal Lancet.The study which observed over 96,000 people hospitalized with COVID-19, showed that people treated with the drug, or the closely related drug chloroquine, had higher risk of death when compared to those who had not been given the medicine.Demand for hydroxychloroquine, a drug approved decades ago, surged after Trump touted its use as a coronavirus treatment in early April. Earlier this week, he surprised the world by admitting he was taking the pill as a preventative medicine.The Lancet study authors suggested these treatment regimens should not be used to treat COVID-19 outside of clinical trials until results from clinical trials are available to confirm the safety and efficacy of these medications for COVID-19 patients. The authors said they could not confirm if taking the drug resulted in any benefit in coronavirus patients.Weeks ago, Trump had promoted the drug as a potential treatment based on a positive report about its use against the virus, but subsequent studies found that it was not helpful. The U.S. Food and Drug Administration in April issued a warning about its use.The Lancet study looked at data from 671 hospitals, where 14,888 patients were given either hydroxychloroquine or chloroquine, with or without the antibiotic macrolide, and 81,144 patients were not on any of the treatment regimens.

See the original post here:
Drug Touted by Trump as COVID-19 Treatment Tied to Increased Death Risk, Study Finds - Voice of America

Read More...

In Online Covid-19 Videos, A Mix of Science and Conjecture – Undark Magazine

May 27th, 2020 11:46 am

In mid-March, filmmaker Robert Cibis at the time best known for a 93-minute documentary about a master piano tuner uploaded a short interview with the German physician and socialist politician Wolfgang Wodarg to YouTube. In the video, Wodarg alleges that the Covid-19 pandemic is a hype drummed up by sensationalist virologists and spread by scientists who want to be important in politics because they need money for their institutions.

Within days, the Wodarg interview had been viewed hundreds of thousands of times (the total now tops 2 million on YouTube), and Cibis and his production company, Oval Media, started raising money for a documentary, called Corona.film. Featuring Wodarg and other scientists, the film is billed as an exploration of the coronavirus and its media influence. On the crowdfunding platform IndieGoGo, hundreds of people have chipped in donations totaling about $105,000 to keep the project going.

The trailer for Corona.film features a high-profile scientist alongside Wodarg: John Ioannidis, a professor of medicine, epidemiology, and population health at Stanford University. Ioannidis co-directs a major center at Stanford that pushes for more rigorous biomedical research; a 2010 Atlantic magazine profile argued that he may be one of the most influential scientists alive. During the current pandemic, while praising public health officials, Ioannidis has criticized the lockdowns as based on too-thin evidence a position that has earned him fierce, albeit respectful,criticismfrom many colleagues. (The pushback intensified this week over a new Ioannidis analysis that many of his colleaguespilloriedonline, with somecitingoversights and inconsistencies in the data included in the study.)

In the teaser, after Wodarg calls for a closer look at the coronavirus epidemic that we allegedly are having right now, Ioannidis explains that, while elements of the pandemic are serious, he thinks there is a very high chance we are exaggerating the risk of the novel coronavirus.

Asked about Corona.film, Ioannidis told Undark he had never heard of it.

As SARS-CoV-2, the coronavirus that causes Covid-19, has swept across the globe, killing hundreds of thousands of people and overwhelming medical systems in the United States, Italy, Ecuador, and other countries, the pandemic has also nurtured a rich ecosystem of digital backlash. To be sure, some people have raised serious and reasonable questions about whether global lockdowns are worth the economic and social cost, which could be especially devastating in some developing countries. But many more hew to unfounded theories that the pandemic is, for example, caused by 5G towers; that it emerged from a lab in China; or that it is the result of a conspiracy by global leaders and plutocrats, especially billionaire Bill Gates.

The story of how footage of the Stanford professor ended up in Corona.film is just one example of how, amid the confusion of the pandemic, the views of serious scientific dissenters are being swiftly metabolized by a sprawling world of ideologues and conspiracy theorists. The tale runs through an independent film distribution company, and it involves a New York-based filmmaking team that has found millions of viewers online through an interview project that features a rich mix of marginal perspectives and pedigreed academics, Ioannidis most prominent among them.

The scientists in the films are not conspiracy theorists, theyre not anti-vaxxers theyre not like us, says one of the filmmakers, John Kirby, who suggested, without citing specific evidence, that the pandemic has been engineered by a global elite seeking to expand itscontrol over the world. But they are incredibly eminent, respected people who are thankfully independent enough to raise a question.

Before the Covid-19 pandemic began, Kirby and his filmmaking partner, Libby Handros, were working on a documentary about the assassinations of the 1960s, including the 1963 murder of President John F. Kennedy, which some people have long-maintained was the result of a government conspiracy. Media coverage of the coronavirus, Kirby told Undark, sounded similar to how they see coverage of the Kennedy assassination: an obfuscation of a deeper, more frightening truth. We sensed a rollout, a very large rollout, Kirby said.

We just want to keep bringing out alternative, sometimes overlapping opinions from experts and journalists.

The filmmakers approached Ioannidis for an interview, producing an hourlong video in which he analyzes the Covid-19 response, speaking in detail about the difficulty of pinning down precise data about a fast-moving pandemic. With the Ioannidis interview in hand, Handros and Kirby pitched the series to Journeyman Pictures, an independent film distributor in the United Kingdom that works with hundreds of documentaries each year.

We saw it as something interesting which would give, exactly as we called it, Perspectives on the Pandemic a broader perspective than we were getting from the increasingly controlled and narrow line being fed to us by the mass media every day, said Mark Stucke, the founder and managing director of Journeyman Pictures.

Journeyman signed Handros and Kirby up and began sharing the Ioannidis video with its 1.4 million YouTube subscribers. Off we went, Stucke said. And boom! It did go boom.

The interview soon picked up hundreds of thousands of views. Thousands also tuned into a conversation with David L. Katz, a physician, former Yale professor, and expert in preventative medicine who has drawn attention for a New York Times op-ed arguing that the negative effects of the lockdowns could outweigh the benefits.

Millions more people watched a viral interview with Knut Wittkowski, a former biostatistician at Rockefeller University who argues that the virus should be allowed to spread unchecked among healthy people until enough people become immune a strategy, widely criticized by experts, that has been partly adopted by the chief epidemiologist in Sweden.

Follow-up conversations with Wittkowski and Ioannidis, in which the latter described the results of his controversial study of Covid-19 prevalence in California, brought hundreds of thousands more views.

In a wide-ranging interview, Kirby and Handros spoke with Undark about the Kennedy assassination, Handros clashes with Donald Trump in the 1990s over a film she made, and Kirbys opposition to current vaccine policies, as well as his suspicion that Bill Gates is planning and manipulating the pandemic response. Most people are not ready to understand that this is not just sort of a public health crisis that governments are doing their best to respond to and maybe screwed up, Kirby said, without offering clear evidence. We just want to keep bringing out alternative, sometimes overlapping opinions from experts and journalists, he added, noting that they may start covering a range of topics. We want to ease people into some of the harder-to-appreciate stuff.

Some of the content in Perspectives on the Pandemic veers more directly into anti-government politics. In the first interview with Wittkowski, published in early April, the scientist said: Im not paid by the government, so Im entitled to actually do science. He also suggested that, left unchecked, the virus could exact a death toll of 10,000 in the U.S. and disappear on its own.

Today, the official U.S. death count is above 90,000, with cases rising in much of the country. In a phone conversation and follow-up emails, Wittkowski defended his projections, arguing that, while specific predictions may not bear out, he was correct to question lockdowns, and that the current death count was dramatically overstated. (There is growing evidence that it is actually an underestimate.) He claimed that the course of the pandemic was as predictable as the effects of gravity. Social distancing is a strategy for the government to reduce the democratic rights of the people, he wrote.

The idea that the Covid-19 pandemic is the result of a conspiracy is ludicrous.

Rockefeller University has publicly distanced itself from Wittkowski, explaining in a statement that comments about discouraging social distancing he has made do not represent the views of The Rockefeller University, its leadership, or its faculty. But his videos for Perspectives on the Pandemic have received widespread attention, including in the New York Post and The Epoch Times an outlet, analysts say, that has been instrumental in pushing the thus-far-unfounded claim that the SARS-CoV-2 virus originated in a Chinese lab and the American Institute for Economic Research, a right-leaning think-tank. Wittkowski has also appeared on an internet talk show hosted by Del Bigtree, a prominent anti-vaccination activist.

Earlier this month, YouTube removed one of Wittkowskis interviews for Perspectives on the Pandemic, citing unspecified violations of its policies. This week, YouTube removed Wittkowskis other interview, as well as the first, long, interview with Ioannidis.

According to YouTube, the Ioannidis video violated the platforms Covid-19 Medical Misinformation Policy, which, among other rules, states that YouTube doesnt allow content that spreads medical misinformation that contradicts the World Health Organization (WHO) or local health authorities medical information about Covid-19. A YouTube spokesperson did not respond to a request on Friday afternoon for specific details about how the Ioannidis interview had violated that policy.

Journeyman Pictures is asking YouTube for clarification regarding the decisions.

After watching the Ioannidis interviews, Cibis approached Journeyman about using the footage in his Covid-19 documentary. The distributor had worked with Oval Media on a previous documentary, also featuring Wodarg, that alleges corruption at the WHO. Stucke agreed, which is how Ioannidis ended up featuring prominently in a trailer for the film, alongside Wodarg, who has continued to argue, despite the mounting global death toll, that the pandemic is largely a fabrication.

Cibis told Undark that he had been surprised and a little frightened by the strong reactions to his original interview with Wodarg, acknowledging that it may have been just naive to publish the video without any research or context. But he rejected characterizations of Wodarg as a conspiracy theorist. His new film, he said, will have diverse perspectives although he added that he has concerns about using footage from one high-ranking Italian public health official who has warned that the virus is particularly dangerous, because Cibis feels it was unscientific and just fear-making.

Stucke, meanwhile, said that while he was aware that Handros and Kirby fit comfortably at the conspiratorial end of the world of journalism, he thought their project seemed sound, and that they were speaking with qualified sources. The Wittkowski interview, though, ultimately gave him pause. He said that if he had seen this interview first and as a standalone piece, rather than in the context of other interviews in the series, I would have probably thought twice about saying Yes, go for it. He admitted to knowing little about certain details of the Cibis project.

Some participating scientists, too, seemed surprised about the context in which their interviews were being presented. Asked whether he was aware of the conspiracy-oriented side to the Perspectives on the Pandemic project, Yale Universitys Katz replied No in an email, adding that the idea that the Covid-19 pandemic was the result of a conspiracy is ludicrous.

The interview was long-form, meaning I could speak my full views so it seemed a good venue, Katz wrote.

All that I really count on the production side to do, he added, is (a) not alter my views by editing them or taking them out of context; [and] (b) give me an audience.

Ioannidis said he was unaware that Journeyman had licensed footage of his interview to the German filmmakers. He also expressed surprise that there might be a conspiracy-oriented dimension to the Perspectives on the Pandemic series. I am clearly not aware of that, he said. Ive talked with John Kirby for two hours during these interviews. None of these questions arose.

People with different conflicts of interest, they will probably use ammunition from perspectives or data or science that has nothing to do with their agenda. It is a concern, Ioannidis said. I do share that concern, but its impossible to censor science, or to, lets say, factor every possible crazy perspective into account before you say, well, These are my data, and this is what I think about them.

But Leah Ceccarelli, a scholar of rhetoric and communication the University of Washington who studies scientific controversy, was skeptical about that line of argument.

Of course, the scientist wants to present the ethos of the disinterested searcher for truth, she said. As a scientist, Im just telling you the way that it is, and its not my job to think about the politics of this.

But that, Ceccarelli said, is totally naive.

Visit link:
In Online Covid-19 Videos, A Mix of Science and Conjecture - Undark Magazine

Read More...

Page 536«..1020..535536537538..550560..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick